Adam's Take

Adam's Take Adam Feuerstein

A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser

Adam's Take Adam Feuerstein

Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen

Adam's Take Adam Feuerstein

A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy

Adam's Take Adam Feuerstein

It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open

Adam's Take Adam Feuerstein

An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more

Adam's Take Adam Feuerstein

Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show

Adam's Take Adam Feuerstein

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Adam's Take Adam Feuerstein

The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

Adam's Take Adam Feuerstein

FDA issues major rebuke to CytoDyn over claims on Covid-19 drug

Adam's Take Adam Feuerstein

Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug

Adam's Take Adam Feuerstein

Fibrogen’s data manipulation scandal came with questions. There need to be answers

Adam's Take Adam Feuerstein

The long wait for Cel-Sci to finally admit its cancer drug doesn’t work

Adam's Take Adam Feuerstein

A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists

Adam's Take Adam Feuerstein

CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment

Adam's Take Adam Feuerstein

Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Adam's Take Adam Feuerstein

Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list

Adam's Take Adam Feuerstein

Why did this small biotech blow up? Because spinning bad drug data never works

Adam's Take Adam Feuerstein

Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles

Adam's Take Adam Feuerstein

Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug

Adam's Take Adam Feuerstein

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Adam's Take Adam Feuerstein

Applied Therapeutics’ muted response to a clinical hold speaks volumes

Adam's Take Adam Feuerstein

CytoDyn is in financial and clinical distress, newly filed annual report shows

Adam's Take Adam Feuerstein

CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure

Adam's Take Adam Feuerstein

CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Adam's Take Adam Feuerstein

Adam’s Take

Most Read

A company developing a human blood substitute attempts a comeback, but IPO plans look dicey

What Regeneron’s purchase of Checkmate Pharma says about the state of biotech

Cel-Sci’s CEO used private call to tip off select investors about cancer drug update

Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent

An FDA rejection derails Omeros, exposing the empty promises of its CEO

Northwest Bio marks ignominious anniversary of brain tumor study delay with silence

In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s

All Coverage

A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser

Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen

A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy

It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open

An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more

Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show

Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

The failure of a cancer drug study leaves Cel-Sci on the brink of collapse

FDA issues major rebuke to CytoDyn over claims on Covid-19 drug

Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug

Fibrogen’s data manipulation scandal came with questions. There need to be answers

The long wait for Cel-Sci to finally admit its cancer drug doesn’t work

A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists

CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment

Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call

Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list

Why did this small biotech blow up? Because spinning bad drug data never works

Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles

Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug

Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

Applied Therapeutics’ muted response to a clinical hold speaks volumes

CytoDyn is in financial and clinical distress, newly filed annual report shows

CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure

CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day